[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-416403-105":59,"doc-detail-416403-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-on-weight-of-a-doravirine-switch-in-people-living-with-hiv","Impact on weight of a Doravirine switch in people living with HIV","","Doravirine is recommended in the 2025 EACS guidelines for people living with HIV, yet real-world evidence on its effect on weight after switching remains limited. This retrospective cohort study analyzed BMI change from 48 months before to 36 months after the switch in patients switching to doravirine across two Parisian hospitals. Among 300 participants, median BMI variation at 12 and 24 months was 0.0 kg/m2 and unchanged by prior treatment, with only slight increases in high-risk subgroups. Switching stabilized weight without reversing previously gained weight.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-on-weight-of-a-doravirine-switch-in-people-living-with-hiv/416403/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-on-weight-of-a-doravirine-switch-in-people-living-with-hiv/416403.png","ImageObject",300,407,{"name":92,"@type":93},"Marglet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective regarding doravirine switching?","Question",{"text":112,"@type":113},"To evaluate weight evolution, specifically BMI variation, in people living with HIV who switched to a doravirine-based antiretroviral regimen in a real-world Paris multicentric cohort.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was BMI variation measured in the cohort study?",{"text":117,"@type":113},"BMI variation was calculated from 48 months before to 36 months after the doravirine switch, using retrospective hospital data.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings on weight after switching to doravirine?",{"text":121,"@type":113},"At 12 and 24 months after switching, median BMI variation was 0.0 kg/m2 and remained unchanged regardless of pre-switch treatment; switching led to weight stabilization without reversing previously gained weight.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},416403,1790740892,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},2336477982702,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","DOI: 10.1111/hiv.70123  \nORIGINAL ARTICLE  \nImpact on weight of a Doravirine switch in people living with HIV  \nNina Garofoli 1  | Philippe Flandre 2  | Jean-Paul Vincensini 1 | Quentin Richier 1  | Priscille Couture 1 | Karine Lacombe 1,2 | Gilles Pialoux 3 | Jean-Luc Meynard 1  \n1Department of Infectious Diseases, Hopitaux de Paris Nord, Saint-Antoine Hospital, Paris, France  \n2INSERM UMR-S1136, Université Sorbonne Paris, Paris, France 3Department of Infectious Diseases, Hopitaux de Paris, Tenon Hospital, Paris, France  \nCorrespondence  \nNina Garofoli, Hopitaux de Paris Nord, Saint-Antoine Hospital, Department of Infectious Diseases, 184 Rue du Faubourg Saint-Antoine, 75012, Paris, France. [Email:](Email: ninagarofoli@gmail.com)[ ninagarofoli@gmail.com](Email: ninagarofoli@gmail.com)  \nAbstract  \nBackground and Objective: Doravirine is among the first-line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti-integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we investigated weight variation in PLHIV switching to doravirine.  \nMethods: A retrospective cohort analysis was conducted in two Parisian hospitals, including all PLHIV switching to doravirine between January 2019 and September 2022 . Body Mass Index (BMI) variation was calculated from 48 months before to 36 months after the switch.  \nResults: Between January 2019 and December 2022, 300 patients were included, with 220 men (73%) and 185 (62%) patients born in France. The main antiretroviral combination before the switch was TAF/FTC/BIC (n = 47, 16%), and after the switch, doravirine with TDF and 3TC (n = 202, 67%) . Twenty-eight patients (9.3%) discontinued doravirine after a median duration of 17 . 5 months. At 12 and 24 months after the switch, the median BMI variation was 0 .0 kg/m2, and this variation remained unchanged regardless of the pre-switch treatment. These results were less pronounced in subgroups of patients originating from sub-Saharan Africa (+0 .2 and +0 .4 kg/m2) and in women (+0 . 3 and 0 . 5 kg/m2) .  \nConclusion: Switching to doravirine led to a weight stabilisation, without reversal of the previously gained weight. In PLHIV at higher risk of weight gain, there was still a slight increase in BMI after the doravirine switch.  \nKEYWOR DS  \nBMI, Doravirine, HIV treatment, switch, weight change  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2025 The Author(s) . HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.  \nBACKGROUND  \nWeight gain under combined antiretroviral therapy (cART) is a major issue in the management of patients living with HIV (PLHIV) in the 21st century. As a result of treatments' efficacy, PLHIV are living longer, increasing their susceptibility to age-related comorbidities. The integrase strand transfer inhibitors (INSTIs), especially dolutegravir and bictegravir, along with tenofovir alafenamide (TAF), are among the first-line treatments most associated with weight gain [1–6] . Other factors associated with weight gain include female sex, Sub-Saharan African ethnicity, age, baseline CD4 count, and HIV viral load [7] . As a result, weight gain in PLHIV can stem from disease-related, treatment-related, and patient-related factors.  \nWeight gain contributes to the disease burden for several reasons. First, excess body weight is a risk factor for the development of cardiovascular diseases and diabetes mellitus in PLHIV. [8, 9] According to Cabyet al., the main causes of death among PLHIV in France between 2016 and 2022 were non-AIDS cancer, as well as neurological and cardiovascular diseases [10] . Moreover, weight","cbCairkDHjSOcoBn","https://ap.wps.com/l/cbCairkDHjSOcoBn","pdf",582451,"English","# Background and Objective\n## Methods\n## Results\n## Conclusion\n# Materials and Methods\n## Study population\n## Background\n## Weight gain in HIV management\n## Rationale for doravirine","[{\"question\":\"What was the study objective regarding doravirine switching?\",\"answer\":\"To evaluate weight evolution, specifically BMI variation, in people living with HIV who switched to a doravirine-based antiretroviral regimen in a real-world Paris multicentric cohort.\"},{\"question\":\"How was BMI variation measured in the cohort study?\",\"answer\":\"BMI variation was calculated from 48 months before to 36 months after the doravirine switch, using retrospective hospital data.\"},{\"question\":\"What were the key findings on weight after switching to doravirine?\",\"answer\":\"At 12 and 24 months after switching, median BMI variation was 0.0 kg/m2 and remained unchanged regardless of pre-switch treatment; switching led to weight stabilization without reversing previously gained weight.\"}]","Impact on weight of a Doravirine switch in people living with HIV | PDF",1790605336,25]